Breaking News

You are here » Indian-Commodity  :  Equity & Shares  :  Cadila Healthcare trades in green on the bourses

14-Jan2019

Cadila Healthcare trades in green on the bourses

Cadila Healthcare is currently trading at Rs. 351.20, up by 2.00 points or 0.57% from its previous closing of Rs. 349.20 on the BSE.

The scrip opened at Rs. 352.00 and has touched a high and low of Rs. 353.40 and Rs. 349.70 respectively.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 450.95 on 15-Jan-2018 and a 52 week low of Rs. 330.65 on 26-Oct-2018.

Last one week high and low of the scrip stood at Rs. 353.40 and Rs. 344.30 respectively. The current market cap of the company is Rs. 35749.09 crore.

The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.34% and 7.87% respectively.

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Betamethasone Dipropionate Cream USP (US RLD - DIPROLENE AF), 0.05%. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad. This medication is a strong corticosteroid and is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Betamethasone reduces the swelling, itching and redness that can occur in these types of conditions.

The group also received a final approval for Amlodipine and Atorvastatin Tablets USP (US RLD - Caduet) in the strengths of 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10mg/80 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. This combination product contains two active ingredients - amlodipine and atorvastatin. Amlodipine reduces blood pressure and the workload on the heart by relaxing the walls of the blood vessels. It is used to lower blood pressure and to treat angina (chest pain). Atorvastatin is used in combination with diet and exercise to treat high cholesterol. It works by blocking an enzyme that is needed to make cholesterol in the body.

The group now has 245 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.


Related News

View all news

United Bank of India shines on getting nod to raise Rs 1,500 crore by various means

United Bank of India is currently trading at Rs. 11.05, up by 0.50 points or 4.74% from its previous closing of Rs. 10.55 on the BSE.The scrip opened at Rs. 10.85 and has touched a high and low of Rs.......

Pondy Oxides & Chemicals gains on planning to merge Meloy Metals with itself

Pondy Oxides & Chemicals is currently trading at Rs. 319.80, up by 1.85 points or 0.58% from its previous closing of Rs. 317.95 on the BSE.The scrip opened at Rs. 317.80 and has touched a high......

Venky's slips on reporting 41.52% fall in Q4 net profit

Venky's  (India) is currently trading at Rs. 1766.00, down by 56.15 points or 3.08% from its previous closing of Rs. 1822.15 on the BSE.The scrip opened at Rs. 1817.00 and has touched a high and......

Top News

View all news

SRF, NIIT Technologies and United Bank of India to see some action today

SRF has entered into a definitive agreement to sell its Engineering Plastics Business to DSM, the Life Sciences and Materials Sciences Company in an all-cash transaction, amounting to Rs 320 crore. The......

NIIT Technologies concludes sale of 88.99% stake in ESRI India Technologies

NIIT Technologies has concluded the sale of 88.99% equity shares in ESRI India Technologies, India to Environment Systems Research Institute Inc., USA. Consequent to above sale, ESRI India Technologies,......

United Bank of India to raise Rs 1,500 crore by various means

United Bank of India has received approval to raise equity capital not exceeding Rs 1,500 crore in one or more tranches during the financial year by way of Qualified Institutions Placement, Public Issue,......